Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Enzyme Replacement Therapy Market?

The market size of enzyme replacement therapy has experienced significant growth in the last several years. The sector will expand from a value of $11.58 billion in 2024 to $12.48 billion in 2025, with a compound annual growth rate (CAGR) projected at 7.8%. The strong growth seen in the historical period can be credited to various factors including advancements in early therapeutic discoveries, groundbreaking treatment approvals, broadened understanding of the disease, clinical success instances, and regulatory support along with incentives.

What Growth Rate Is Forecasted for the Enzyme Replacement Therapy Market by 2029?

In the upcoming years, the size of the enzyme replacement therapy market is projected to witness a robust expansion. It’s set to escalate to “$17.81 billion by 2029, with a high compound annual growth rate (CAGR) of 9.3%. This expected growth during the forecast period can be linked to a rise in patients’ access to healthcare services, customized treatment options and personalized healthcare, changes in healthcare regulations, and increased awareness among patient populace. Major trends for this forecast timeframe encompass integration of digital health, focus towards patient-centered solutions, ongoing biomarker research, and the application of precision medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample_request?id=10512&type=smp

Which Key Companies Are Shaping the Future of the Enzyme Replacement Therapy Market?

Major companies operating in the enzyme replacement therapy market include Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Recordati Rare Diseases Inc., Sangamo Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Horizon Pharma Public Limited Company, Protalix Biotherapeutics Ltd., Amicus Therapeutics Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Retrophin Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Ultragenyx Pharmaceutical Inc.

Which Factors Are Driving Demand in the Enzyme Replacement Therapy Industry?

The surge in uncommon, chronic, and genetic diseases is anticipated to spur the expansion of the enzyme replacement therapy market in the future. Chronic diseases are defined as illnesses that persist for more than three months and may worsen over time. Such diseases are prevalent amongst the elderly, and while they can be managed, they cannot be entirely eliminated. For example, the American Lung Association, a non-profit organization based in the US, reported in July 2024 that the number of Americans diagnosed with asthma by a health professional increased to 44.2 million or 13.5% of the population in 2022, up from 12.9% in 2021. Therefore, the increasing incidence of uncommon, chronic, and genetic diseases will fuel the advancement of the enzyme replacement therapy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/Customise?id=10512&type=smp

How Is the Enzyme Replacement Therapy Market Segmented by Several Divisions?

The enzyme replacement therapy market covered in this report is segmented –

1) By Enzyme Type: Agalsidase Alfa, Agalsidase Beta, Galsulfase, Other Enzyme Types

2) By Route Of Administration: Oral, Parenteral

3) By Application: Gaucher Disease, Pompe Disease, Fabry Disease, Other Applications

4) By End-Users: Hospitals, Infusion Centers, Other End-Users

Subsegments:

1) By Agalsidase Alfa: Fabry Disease Treatment

2) By Agalsidase Beta: Fabry Disease Treatment

3) By Galsulfase: Mucopolysaccharidosis VI (MPS VI) Treatment

4) By Other Enzyme Types: Alglucosidase Alfa, Idursulfase, Velaglucerase Alfa

What are the Emerging Market Trends Driving the Growth of the Enzyme Replacement Therapy Industry?

A key trend emerging in the enzyme replacement therapy market is the gaining popularity of product approvals. Numerous enzyme replacement therapy drugs developed by major companies are now getting approved. To exemplify, in February 2023, Lamzede (velmanase alfa), the pioneering enzyme replacement therapy approved in the United States for treating non-central neurological symptoms of alpha-mannosidosis, was given the green light by the Food and Drug Administration, a US federal agency under the Department of Health. This rare genetic disorder is described by a lack of the alpha-mannosidase enzyme in the body. Lamzede serves as a substitute for this enzyme to restore normal cellular operations. It is administered as a 10mg injection to patients on a weekly basis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/enzyme-replacement-therapy-global-market-report

Which Regions Are Driving Growth in the Enzyme Replacement Therapy Market?

North America was the largest region in the enzyme replacement therapy market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global enzyme replacement therapy market report during the forecast period. The regions covered in the enzyme replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10512

This Report Delivers Insight On:

1. How big is the enzyme replacement therapy market, and how is it changing globally?

2. Who are the major companies in the enzyme replacement therapy market, and how are they performing?

3. What are the key opportunities and risks in the enzyme replacement therapy market right now?

4. Which products or customer segments are growing the most in the enzyme replacement therapy market?

5. What factors are helping or slowing down the growth of the enzyme replacement therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model